TLR4 and fatty liver disease: These results are consistent with the conclusions obtained in obese rats treated with Ang1-7 (Santos et al., 2013) and transgenic rats overexpressing Ang1-7 (Bilman et al., 2012), which alleviate hepatic steatosis and TLR4/MAPK/NF-κB signaling activity inhibition.